Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Expert
Dr Alexander Röth, University of Duisburg-Essen, Germany
Conference
ASH 2019
Trial
Phase 3, CARDINAL

In a phase 3 clinical trial, patients with cold agglutinin disease (CAD) treated with sutimlimab demonstrated improved haemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued [1].

Sutimlimab is a first-in-class humanised monoclonal antibody that selectively inhibits the C1 complex of the classical complement pathway. Since C1 complement pathway overactivation is thought to drive CAD pathogenesis, the rationale was to evaluate whether sutimlimab could modify key disease outcomes such as haemolytic anaemia. There are currently no approved treatments for CAD.

Dr Alexander Röth (University of Duisburg-Essen, Germany) presented Part A of the open-label, single-arm, multicentre CARDINAL study, in which 22 CAD patients (average age of 71 years) received intravenous sutimlimab on days 0 and 7, followed by biweekly infusions for 26 weeks. Part B is the ongoing e...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on